中草药

三叶青醇提物对4T1乳腺癌的体内外抑制作用及其对TNF-α/Akt/STAT3信号轴的调控机制

PDF下载

中草药 | 药理与临床 2026,57(10): 3861-3877

收起

中草药 |药理与临床 2026 , 57 (10) : 3861 -3877

三叶青醇提物对4T1乳腺癌的体内外抑制作用及其对TNF-α/Akt/STAT3信号轴的调控机制

全屏

邵杨洁¹, 凌立君², 于瑞莲¹, 刘学湘¹, 崔爱平¹, 陈家龙¹, 宋栋¹, 朱宇航¹

作者信息

通讯作者:

于瑞莲

作者简介:

邵杨洁: 邵杨洁(2001—),女,硕士,研究方向为中药效应与安全性评价。E-mail:754156285@qq.com

Inhibitory effects of ethanol extract of Tetrastigma hemsleyanum on 4T1 breast cancer in vivo and in vitro and its regulatory mechanism on TNF-α/Akt/STAT3 signaling axis

SHAO Yangjie, LING Lijun, YU Ruilian, LIU Xuexiang, CUI Aiping, CHEN Jialong, SONG Dong, ZHU Yuhang

Affiliations

doi: 10.7501/j.issn.0253-2670.2026.10.016

文章导航

摘要

收起

目的鉴定三叶青醇提物（ethanol extract of Tetrastigma hemsleyanum，SYQ）入血成分并探讨其抗4T1乳腺癌的作用机制。方法采用超高效液相色谱-四极杆-飞行时间串联质谱（ultra-high performance liquid chromatography-quadrupole time-of-flight tandem mass spectrometry，UHPLC-Q-TOF-MS/MS）分析SYQ的入血成分；通过MTT法、克隆形成与划痕实验检测SYQ含药血清对4T1乳腺癌细胞增殖和迁移的影响。构建4T1荷瘤小鼠模型，设置对照组、模型组、环磷酰胺（20 mg/kg）组和SYQ低、中、高剂量（5、10、20 g/kg）组，给药干预后，ELISA检测血清中白细胞介素-6（interleukin-6，IL-6）和肿瘤坏死因子-α（tumor necrosis factor-α，TNF-α）水平；苏木素-伊红（hematoxylin-eosin，HE）染色观察肿瘤组织病理变化；免疫组化检测肿瘤组织CD68和Ki67表达；Western blotting法检测肿瘤组织中TNF-α/蛋白激酶B（protein kinase B，Akt）/信号传导与转录激活因子3（signal transducer and activator of transcription 3，STAT3）信号轴及凋亡相关蛋白表达。结果 UHPLC-Q-TOF-MS/MS鉴定出19种入血成分，主要包括黄酮类（芦丁、橘皮素、水仙苷）以及苯丙素类和其他苷类化合物（连翘苷E、达伦苷B）。体外实验结果显示，SYQ含药血清显著抑制4T1细胞增殖、迁移及克隆形成（P＜0.01、0.001）。体内实验结果显示，SYQ显著抑制荷瘤小鼠肿瘤体积增长（P＜0.001），高剂量组抑瘤率达25.95%；降低血清中IL-6和TNF-α水平（P＜0.05、0.001），诱导肿瘤组织坏死并显著降低CD68和Ki67表达（P＜0.001），同时下调肿瘤组织中TNF-α、p-Akt/Akt、p-STAT3/STAT3及B细胞淋巴瘤-2（B-cell lymphoma-2，Bcl-2）表达水平（P＜0.05、0.01、0.001）。结论 SYQ可通过降低炎症因子水平、抑制肿瘤细胞增殖及诱导肿瘤组织坏死，从而发挥抗乳腺癌作用，其机制可能与抑制TNF-α/Akt/STAT3信号轴有关。

关键词

三叶青 / 血清药物化学 / 乳腺癌 / 炎症 / Akt/STAT3信号通路 / 芦丁 / 橘皮素 / 水仙苷 / 连翘苷E / 达伦苷B

Abstract

收起

Objective To identify the blood-absorbed constituents of ethanol extract of Tetrastigma hemsleyanum (SYQ) and investigate its anti-breast cancer activity and underlying mechanisms. Methods Blood-absorbed components of SYQ were identified using ultra-high performance liquid chromatography-quadrupole time-of-flight tandem mass spectrometry. The effects of SYQ drug containing serum on proliferation and migration of 4T1 cells were evaluated by MTT, colony formation and wound-healing assays. A 4T1 tumor-bearing mouse model was established, control group, model group, cyclophosphamide (20 mg/kg) group, SYQ low-, medium-, and high-dose (5, 10, 20 g/kg) groups were set up. After drug intervention, ELISA was used to detect the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in serum. Hematoxylin-eosin (HE) staining was used to observe pathological changes in tumor tissue. Immunohistochemistry was used to detect CD68 and Ki67 expressions in tumor tissue. Western blotting was used to detect the expressions of TNF-α/protein kinase B (Akt)/signal transducer and activator of transcription 3 (STAT3) signaling axis and apoptosis related proteins in tumor tissues. Results A total of 19 blood components were identified by UHPLC-Q-TOF-MS/MS, mainly including flavonoids (rutin, tangeretin, narcissoside), phenylpropanoids, and other glycoside compounds (forsythoside E, darendoside B). The in vitro experimental results showed that SYQ drug containing serum significantly inhibited the proliferation, migration and colony formation of 4T1 cells (P < 0.01, 0.001). The in vivo experimental results showed that SYQ significantly inhibited tumor volume growth in tumor bearing mice (P < 0.001), with a tumor inhibition rate of 25.95% in high-dose group. SYQ reduced the levels of IL-6 and TNF-α in serum (P < 0.05, 0.001), induced tumor tissue necrosis and significantly reduced the expressions of CD68 and Ki67 (P < 0.001), while downregulated the expression levels of TNF-α, p-Akt/Akt, p-STAT3/STAT3 and B-cell lymphoma-2 (Bcl-2) in tumor tissue (P < 0.05, 0.01, 0.001). Conclusion SYQ could exerts anti-breast cancer effects by reducing the levels of inflammatory factors, inhibiting tumor cell proliferation and inducing tumor tissue necrosis. The mechanism may be related to the inhibition of TNF-α/Akt/STAT3 signaling axis.

Key words

Tetrastigma hemsleyanum Diels et Gilg / serum pharmacochemistry / breast cancer / inflammation / Akt/STAT3 signaling pathway / rutin / tangeretin / narcissoside / forsythoside E / darendoside B

引用本文

邵杨洁, 凌立君, 于瑞莲, 刘学湘, 崔爱平, 陈家龙, 宋栋, 朱宇航. 三叶青醇提物对4T1乳腺癌的体内外抑制作用及其对TNF-α/Akt/STAT3信号轴的调控机制. 中草药, 2026 , 57 (10) : 3861 -3877 . DOI: 10.7501/j.issn.0253-2670.2026.10.016

SHAO Yangjie, LING Lijun, YU Ruilian, LIU Xuexiang, CUI Aiping, CHEN Jialong, SONG Dong, ZHU Yuhang. Inhibitory effects of ethanol extract of Tetrastigma hemsleyanum on 4T1 breast cancer in vivo and in vitro and its regulatory mechanism on TNF-α/Akt/STAT3 signaling axis[J]. Chinese Traditional and Herbal Drugs, 2026 , 57 (10) : 3861 -3877 . DOI: 10.7501/j.issn.0253-2670.2026.10.016

基金

收起

江苏省人民医院专项发展基金 (ZXFZ2026017); 南京中医药大学中药学一级重点学科开放项目 (ZYXPY2024-008)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

Nolan E, Lindeman G J, Visvader J E. Deciphering breast cancer: From biology to the clinic [J]. Cell, 2023, 186(8): 1708-1728.
李萍萍. 中医药治疗乳腺癌述评[J]. 北京中医药大学学报, 2023, 46(11): 1616-1622.
Loibl S, André F, Bachelot T, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up [J]. Ann Oncol, 2024, 35(2): 159-182.
鲍敏, 陈群, 赵森. 中药治疗乳腺癌的药理作用机制和临床应用研究进展[J]. 中草药, 2025, 56(21): 7983-7994.
Wu Q Y, Xu X G, Liu H, et al. Efficacy and safety of Huachansu Capsule as adjuvant therapy for breast cancer: A systematic review and Meta-analysis of randomized controlled trials [J]. J Ethnopharmacol, 2025, 353(Pt B): 120464.
Zhao M J, Jin C, Xu J W, et al. Polysaccharide from Tetrastigma hemsleyanum Diels et Gilg attenuates Poly(I: C)-induced acute lung injury by preserving epithelial barrier integrity and modulating STING/TBK1-NF-κB and IRF1-STAT1 signaling [J]. J Ethnopharmacol, 2026, 360: 121192.
张云飞, 叶春林, 陈信佳. 三叶青黄酮调控AMPK/ mTOR信号通路介导的线粒体自噬抑制肝癌细胞增殖与侵袭的分子机制研究[J]. 药物评价研究, 2025, 48(8): 2135-2144.
Fang Y K, Ning A H, Li S, et al. Polysaccharides extracted from rhizoma pleionis have antitumor properties in vitro and in an H22 mouse hepatoma ascites model in vivo [J]. Int J Mol Sci, 2018, 19(5): 1386.
Hanahan D. Hallmarks of cancer: New dimensions [J]. Cancer Discov, 2022, 12(1): 31-46.
Liu J, Wang S, Zhang Y, et al. Traditional Chinese medicine and cancer: History, present situation, and development [J]. Thorac Cancer, 2015, 6(5): 561-569.
Zhang L, Li Z Y, Skrzypczynska K M, et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer [J]. Cell, 2020, 181(2): 442-459.
Zhou F M, Lu Y, Sun T, et al. Antitumor effects of polysaccharides from Tetrastigma hemsleyanum Diels et Gilg via regulation of intestinal flora and enhancing immunomodulatory effects in vivo [J]. Front Immunol, 2022, 13: 1009530.
Luo W, Huang R F, Tao Y. Bridging traditional knowledge and modern science: A systematic review of Ampelopsis japonica with emphasis on novel anti-cancer compounds, polypharmacology and clinical translation potential [J]. J Ethnopharmacol, 2026, 356: 120835.
Nouri Z, Fakhri S, Nouri K, et al. Targeting multiple signaling pathways in cancer: The rutin therapeutic approach [J]. Cancers, 2020, 12(8): 2276.
Raza W, Luqman S, Meena A. Prospects of tangeretin as a modulator of cancer targets/pathways [J]. Pharmacol Res, 2020, 161: 105202.
Wu B X, Yu X C, Li Y L, et al. Forsythoside E alleviates liver injury by targeting PKM2 tetramerization to promote macrophage M2 polarization [J]. Adv Sci, 2026, 13(6): e14514.
Zheng W L, Wang H N, Wang X, et al. Kaempferol 3-O-rutinoside, a flavone derived from Tetrastigma hemsleyanum Diels et Gilg, reduces body temperature through accelerating the elimination of IL-6 and TNF-α in a mouse fever model [J]. Molecules, 2024, 29(7): 1641.
Fernandes Q, Inchakalody V P, Bedhiafi T, et al. Chronic inflammation and cancer the two sides of a coin [J]. Life Sci, 2024, 338: 122390.
Yeung K T, Yang J. Epithelial-mesenchymal transition in tumor metastasis [J]. Mol Oncol, 2017, 11(1): 28-39.
Jin H, Meng X Y, Feng J W. Mechanisms of tumor-associated macrophages in breast cancer and treatment strategy [J]. Front Immunol, 2025, 16: 1560393.
Lin Y X, Xu J X, Lan H Y. Tumor-associated macrophages in tumor metastasis: Biological roles and clinical therapeutic applications [J]. J Hematol Oncol, 2019, 12(1): 76.
Coussens L M, Werb Z. Inflammation and cancer [J]. Nature, 2002, 420(6917): 860-867.
Di Meglio A, Havas J, Pagliuca M, et al. A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance 2 years later [J]. Ann Oncol, 2024, 35(11): 1048-1060.
Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey [J]. Blood, 2012, 119(3): 651-665.
Cruceriu D, Baldasici O, Balacescu O, et al. The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: Molecular insights and therapeutic approaches [J]. Cell Oncol, 2020, 43(1): 1-18.
Mardiana L, Milanda T, Hadisaputri Y E, et al. Anticancer mechanisms of Poikilospermum suaveolens root fraction: Ethnopharmacological relevance, signaling pathways, and in vitro/in silico studies on MCF-7 cells [J]. J Ethnopharmacol, 2026, 361: 121177.
Yu H, Lee H, Herrmann A, et al. Revisiting STAT3 signalling in cancer: New and unexpected biological functions [J]. Nat Rev Cancer, 2014, 14(11): 736-746.
Samad M A, Ahmad I, Hasan A, et al. STAT3 signaling pathway in health and disease [J]. MedComm, 2025, 6(4): e70152.
Ihara S, Kida H, Arase H, et al. Inhibitory roles of signal transducer and activator of transcription 3 in antitumor immunity during carcinogen-induced lung tumorigenesis [J]. Cancer Res, 2012, 72(12): 2990-2999.
Zughaibi T A, Suhail M, Tarique M, et al. Targeting PI3K/ Akt/mTOR pathway by different flavonoids: A cancer chemopreventive approach [J]. Int J Mol Sci, 2021, 22(22): 12455.
Qin J J, Yan L, Zhang J, et al. STAT3 as a potential therapeutic target in triple negative breast cancer: A systematic review [J]. J Exp Clin Cancer Res, 2019, 38(1): 195.
Johnson D E, O’Keefe R A, Grandis J R. Targeting the IL-6/JAK/STAT3 signalling axis in cancer [J]. Nat Rev Clin Oncol, 2018, 15(4): 234-248.
何佳奇, 李娟娟, 吕晓皑, 等. 三叶青总黄酮逆转吉非替尼耐药肺腺癌细胞的耐药性[J]. 中国临床药理学与治疗学, 2021, 26(4): 368-375.
Kim J Y, Park C S, Jang S K, et al. The significance of p-AKT1 as a prognostic marker and therapeutic target in patients with hormone receptor-positive and human epidermal growth factor receptor-2-positive early breast cancer [J]. J Breast Cancer, 2022, 25(5): 387.
Chen S P, Luo M X, Ma L, et al. Ethylacetate extract from Tetrastigma hemsleyanum inhibits proliferation and induces apoptosis in HepG2 and SMMC-7721 cells [J]. Cancer Manag Res, 2018, 10: 3793-3799.
Xiang Y N, Guo Z M, Zhu P F, et al. Traditional Chinese medicine as a cancer treatment: Modern perspectives of ancient but advanced science [J]. Cancer Med, 2019, 8(5): 1958-1975.
Dostert C, Grusdat M, Letellier E, et al. The TNF family of ligands and receptors: Communication modules in the immune system and beyond [J]. Physiol Rev, 2019, 99(1): 115-160.
da Silva M F, Lins A A, Gomes M C, et al. Anticancer drug discovery from natural compounds targeting PI3K/AKT/ mTOR signaling pathway [J]. Curr Med Chem, 2025, 32(24): 4859-4887.
Manning B D, Toker A. AKT/PKB signaling: Navigating the network [J]. Cell, 2017, 169(3): 381-405.
Kaneko T, Zhang Z C, Mantellini M G, et al. Bcl-2 orchestrates a cross-talk between endothelial and tumor cells that promotes tumor growth [J]. Cancer Res, 2007, 67(20): 9685-9693.
Czabotar P E, Lessene G, Strasser A, et al. Control of apoptosis by the Bcl-2 protein family: Implications for physiology and therapy [J]. Nat Rev Mol Cell Biol, 2014, 15(1): 49-63.

2026年第57卷第10期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.7501/j.issn.0253-2670.2026.10.016

接收时间：2026-02-08
首发时间：2026-09-09

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2026-02-08

基金

作者信息

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zcy/CN/10.7501/j.issn.0253-2670.2026.10.016

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT